Corcept Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $761.4M | $675.0M | $482.4M | $401.9M | $366.0M | $353.9M | $306.5M | $251.2M |
| Cost of Revenue | $13.0M | $10.9M | $6.5M | $5.4M | $5.3M | $5.6M | $5.5M | $5.2M |
| Gross Profit | $748.4M | $664.2M | $475.9M | $396.5M | $360.7M | $348.3M | $301.0M | $246.0M |
| Gross Margin | 98.3% | 98.4% | 98.7% | 98.7% | 98.6% | 98.4% | 98.2% | 97.9% |
| Operating Expenses | ||||||||
| Research & Development | $254.9M | $246.9M | $184.4M | $131.0M | $113.9M | $114.8M | $89.0M | $75.2M |
| SG&A Expense | $448.7M | $280.3M | $184.3M | $152.8M | $122.4M | $105.3M | $100.4M | $81.3M |
| Operating Income | $44.8M | $137.0M | $107.3M | $112.6M | $124.5M | $128.2M | $111.6M | $89.5M |
| Operating Margin | 5.9% | 20.3% | 22.2% | 28.0% | 34.0% | 36.2% | 36.4% | 35.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $66.5M | $161.5M | $124.6M | $116.2M | $125.0M | $131.6M | $116.7M | $92.2M |
| Income Tax Expense | $-33.2M | $20.3M | $18.4M | $14.8M | $12.5M | $25.6M | $22.5M | $16.7M |
| Net Income | $99.7M | $141.2M | $106.1M | $101.4M | $112.5M | $106.0M | $94.2M | $75.4M |
| Net Margin | 13.1% | 20.9% | 22.0% | 25.2% | 30.7% | 30.0% | 30.7% | 30.0% |
| EPS (Basic) | $0.95 | $1.35 | $1.02 | $0.95 | $0.97 | $0.92 | $0.82 | $0.65 |
| EPS (Diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 | $0.85 | $0.77 | $0.60 |
| Shares Outstanding (Basic) | 103.9M | 103.2M | 103.6M | 106.8M | 115.7M | 115.4M | 114.3M | 115.3M |
| Shares Outstanding (Diluted) | 120.0M | 113.5M | 111.7M | 116.0M | 126.0M | 124.2M | 122.6M | 126.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |